EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4

Aruni Ghose iD, Lucy McCann, Shania Makker iD, Uma Mukherjee, Sri Vidya Niharika Gullapalli, Jayaraj Erekkath, Stephanie Shih, Ishika Mahajan, Elisabet Sanchez, Mario Uccello, Michele Moschetta, Sola Adeleke iD und 1 weitere

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359241233225 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 29.02.2024. Verfasst von Aruni Ghose und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Barts Cancer Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer (OC) is the most lethal gynaecologic malignancy, attributed to its insidious growth, non-specific symptoms and late presentation. Unfortunately, current screening modalities are inadequate at detecting OC and many lack the appropriate specificity and sensitivity that is desired from a screening test. Nearly 70% of cases are diagnosed at stage III or IV with poor 5-year overall survival. Therefore, the development of a sensitive and specific biomarker for early diagnosis and screening for OC is of utmost importance. Currently, diagnosis is guided by CA125, the patient’s menopausal status and imaging features on ultrasound scan. However, emerging evidence suggests that a combination of CA125 and HE4 (another serum biomarker) and patient characteristics in a multivariate index assay may provide a higher specificity and sensitivity than either CA125 and HE4 alone in the early detection of OC. Other attempts at combining various serum biomarkers into one multivariate index assay such as OVA1, ROMA and Overa have all shown promise. However, significant barriers exist before these biomarkers can be implemented in clinical practice. This article aims to provide an up-to-date review of potential biomarkers for screening and early diagnosis of OC which may have the potential to transform its diagnostic landscape.

Schlagwörter

Stichwörter der Autor:innen

circulating tumour biomarkersdiagnostic biomarkersmolecular testingovarian cancertumour biomarkers

Autor:innen und Institutionen

  • Department of Medical Oncology, Barts Cancer Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
  • Department of General Medicine, Newham University Hospital, Barts Health NHS Trust, London, UK.
  • Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, UK.
  • Department of Medical Oncology, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, London, UK.
  • Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
  • Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

ORCID-Profile: Aruni Ghose, Shania Makker, Sola Adeleke

Förderung

  • Cancer Research UK

Zitieren

APA

Ghose, A., McCann, L., Makker, S., Mukherjee, U., Gullapalli, S. V. N., Erekkath, J., Shih, S., Mahajan, I., Sanchez, E., Uccello, M., Moschetta, M., Adeleke, S., & Boussios, S. (2024). Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241233225

Vancouver

Ghose A, McCann L, Makker S, Mukherjee U, Gullapalli SVN, Erekkath J, et al. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241233225

BibTeX
@article{Ghose2024,
  author = {Ghose, Aruni and McCann, Lucy and Makker, Shania and Mukherjee, Uma and Gullapalli, Sri Vidya Niharika and Erekkath, Jayaraj and Shih, Stephanie and Mahajan, Ishika and Sanchez, Elisabet and Uccello, Mario and Moschetta, Michele and Adeleke, Sola and Boussios, Stergios},
  title = {Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359241233225}
}
Kostenlos starten →